Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis)
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
International immunopharmacology - 70(2019) vom: 01. Mai, Seite 67-68 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tavakolpour, Soheil [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 19.07.2019 Date Revised 19.07.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2019.01.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294102833 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294102833 | ||
| 003 | DE-627 | ||
| 005 | 20231225080752.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2019.01.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0980.xml |
| 035 | |a (DE-627)NLM294102833 | ||
| 035 | |a (NLM)30785092 | ||
| 035 | |a (PII)S1567-5769(18)31261-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tavakolpour, Soheil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2019 | ||
| 500 | |a Date Revised 19.07.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Cyclophosphamide | |
| 650 | 4 | |a Granulomatosis with polyangiitis | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a Wegener's Granulomatosis | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Alesaeidi, Samira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 70(2019) vom: 01. Mai, Seite 67-68 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2019 |g day:01 |g month:05 |g pages:67-68 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2019.01.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2019 |b 01 |c 05 |h 67-68 | ||